Perrigo Company plc (PRGO) Price Prediction 2026–2050

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.

It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.

The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands.

The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013.

Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Perrigo Company plc (PRGO) is currently trading at $11.22 per share, with a market capitalization of $1.55B and a rank of 2203.

The current price and capitalization place Perrigo among smaller-cap healthcare equities with a global OTC focus. The near-term outlook references a neutral stance, while the longer horizon shows significant upside potential according to the year-by-year forecasts.

Forecasts indicate a neutral stance in 2026 with an average price of $11.22, rising into a bullish trajectory from 2031 onward as averages climb toward multi-decade highs.

The 30-day technical landscape shows a defined trading band around the current level, with a low- to high-range that hints at continued volatility in the near term, before a stronger long-run uptrend emerges in the forecast window.

From 2031 onward, the forecast turns bullish with rising averages and sizable upside potential. The 2031 forecast shows an average of $14.10, a max of $20.36, and an ROI of 25.6, with the 2032 forecast at an average of $16.91 and a max of $24.84 (ROI 50.7). The 2033 forecast also shows a high likelihood of upside, with an average of $16.93 and a max of $25.25 (ROI 50.9), followed by 2034 with an average of $18.04 and a max of $27.28 (ROI 60.8) and 2035 with an average of $18.74 and a max of $28.72 (ROI 67).

By 2040, the forecast projects an average of $27.54, a min of $18.43, and a max of $44.59, with an ROI of 145.5 and a bullish sentiment.

By 2050, the forecast shows an average of $42.32, a min of $25.78, and a max of $74.30, with an ROI of 277.1 and a bullish sentiment.

Overall, longer-term projections depict meaningful upside from the early 2030s through 2050, though these figures are estimates and not guarantees. Investors should consider the implied risks and the possibility of divergent outcomes in any forward-looking outlook.